ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2793

Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives

Elizabeth Salt1, Mary Kay Rayens 2, Leslie Crofford 3 and Jamie Studts 2, 1University of Kentucky, Lexington, KY, 2University of Kentucky, Lexington, 3Vanderbilt University, Nashville

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: methotrexate (MTX) and qualitative, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T101: Clinical Aspects & Outcomes Research (2792–2797)

Session Type: ARP Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: An estimated 11% to 33% of persons taking methotrexate for rheumatoid arthritis (RA) are reported to be at least moderately intolerant to this medication. The published literature has largely measured methotrexate intolerance using a scale composed of four domains: abdominal pain, nausea, vomiting and behavioral symptoms. These symptoms largely ignore the definition of “intolerance” or the “unwillingness or refusal to tolerate or respect opinions or beliefs contrary to one’s own”. As such, the patients’ perspective is not captured. The purpose of this study is to use qualitative methodologies to describe methotrexate intolerance from the adult patient with RA’s perspective.

Methods: We conducted semi-structured audio-recorded individual interviews with 14 adult English-speaking patients who have a rheumatology health-care provider confirmed diagnosis of RA, and who had been prescribed, were taking, or had ever taken oral or subcutaneous methotrexate. We identified 489 labels for common words or phrases or codes during line-by-line coding which were categorized using constant comparative analysis and then collapsed into three central themes.

Results: Findings from the conducted interviews suggest that methotrexate intolerance is a construct conceptualized from three themes: Beliefs about the Risk of Methotrexate, Beliefs about the Benefits of Methotrexate, and Beliefs about the Threat of RA. The complex beliefs about methotrexate involved both perceived risks and benefits which resulted from knowledge obtained from sources with varying perceived value such as the Internet, others with RA, or their health care provider. The experiences of trusted peers with RA and the relationship with their health care provider were influential in the decision to tolerate methotrexate. The amount of information and timing in which to participants’ sought information varied.

Participants also described beliefs about the threat of RA which often resulted from personal experiences with pain and difficulty functioning or observing the experiences of other with RA. Patients often reported the desire to avoid “being crippled” or requiring the use of assistive devices including a wheel chair. The belief in the perceived benefit of methotrexate, which was often improved functioning in activities of daily living, and threat of the RA hindering this functioning often was a stimulus to tolerate perceived risks or to take methotrexate despite known risks (e.g., hair loss and nausea).

Conclusion: Findings from this study suggest that intolerance to methotrexate involves a complex belief system where patients with RA weigh beliefs about risks and benefits of methotrexate alongside beliefs about the threat of RA.


Disclosure: E. Salt, Pfizer, 2, Pfizer and IHI, 2; M. Rayens, Pfizer, 2, Pfizer and IHI, 2; L. Crofford, None; J. Studts, Pfizer, 2.

To cite this abstract in AMA style:

Salt E, Rayens M, Crofford L, Studts J. Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methotrexate-intolerance-a-qualitative-descriptive-study-of-the-adult-rheumatoid-arthritis-patients-perspectives/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-intolerance-a-qualitative-descriptive-study-of-the-adult-rheumatoid-arthritis-patients-perspectives/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology